Aeglea BioTherapeutics Investor Presentation Deck

Spyre aims to build on this success with combinations of potentially best-in-class mAbs from favorable MOAS Targets Format Monotherapies lack black box warning Anti-cytokine + anti-lymphocyte trafficking Half-life extension Q8-12W dosing Source: Company materials SPYRE SPY130 a437 + IL-23 Co-formulation SPY120 a437 + TL1A Co-formulation SPY230 TL1A + IL-23 Co-formulation JNJ-'4804 TNF + IL-23 Co-formulation 31

View entire presentation